About The Louisiana Research Center, LLC
The Louisiana Research Center, LLC is a clinical research center owned and operated by gastroenterologists who are also partners in the group practice of GastroIntestinal Specialists, A.M.C. The Center is able to serve you with two locations. The practice has participated in investigational studies since 1992, and the successful completion of these studies led to the formation of Louisiana Research Center. There are three full-time research coordinators on staff.
The consistent ability to recruit and enroll patients and complete studies in a timely and professional manner has resulted in a high level of satisfaction for both clinical research organizations and sponsoring pharmaceutical companies.
Since 1992 we have participated in and completed studies involving peptic ulcer disease (with Helicobacter pylori), erosive esophagitis, gastroesophageal reflux disease, non-erosive esophagitis, anal-rectal disease, chronic constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease, and hepatitis C.
We have also performed studies in healthy volunteers to study the possible effects of medications on the gastrointestinal tract. Louisiana Research Center is actively pursuing participation in additional gastrointestinal studies.
- Associated with the largest group of board certified gastroenterologists in the Ark-La-Tex.
- Utilizes a centralized institutional review board (IRB).
- Adheres to Good Clinical Practice Guidelines.
- Has access to a large population base with a diverse array of pathology.
- Utilizes the Shreveport Endoscopy Center for studies requiring endoscopic procedures.
- Has been highly successful in patient recruitment.
- Has an excellent record of timely completion of studies with accurate and complete source documents.
Initiation of induction of infliximab or adalimumab within the last 24 weeks
Active endoscopic disease
Must have IDA caused by different aetiologies* such as abnormal uterine bleed-ing, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss.
A documented history of intolerance to oral iron therapy for at least one month within 9 months prior to trial enrollment
Hb ≤ 10 g/dL
- TSAT < 20 %
- S-ferritin < 100 ng/mL
Prometheus Blood Draw and Optional Stool Collection
Pt must have been dx with IBD and be scheduled for a colonoscopy, excluded if the pt has received blood products in the last 3 months
Prometheus/Nestle for Moderate to Severe UC
Must be failing oral 5-ASA ≥2.4g/day, pt must not have been exposed to any other treatment in the last 8 weeks
GenFit, Intercept, Conatus, and Gilead NASH
Fibrosis stage 1-3
Gilead study enrolling compensated cirrhosis patients
Uncontrolled diabetes, Cirrhosis and other Chronic Liver Diseases excluded
Pt must be willing to have 2 liver Biopsies
Takeda Observational Study A For Crohn`s and UC
Initiated a biologic within 2 weeks of enrollment
Shire Eosinophilic Esophagitis
Histologic evidence of EOE
Non responsive to high dose PPI`s
Celgene, Janssen, Takeda, Gilead, Abbvie, Eli Lily and Genentech Crohn’s
18 years or older
Moderate to severely active Crohn’s disease
C - Diﬀ Vaccine
50 years or older
At least 1 hospitalization > 2 nights in duration previous 12 month
At least 2 ER visits in the previous 12 months or
At least 10 outpatient visits in the previous 12 months
Residence in a skilled nursing facility or nursing home
Received systemic antibiotics at any time in the previous 12 weeks
No prior episodes of C-Diff
No bleeding disorders
No bowel resections
Abbvie, Genetech, Gilead, Takeda, and Protagonist - Moderate to Severe Ulcerative Colitis
18-80 years of age
Diagnosis of UC established at least 3-6 months prior to Day 1
Evidence of UC extending a minimum of 20 cm from the anal verge determine by baseline Endoscopy